New therapeutic options providing a long-term benefit or even a cure are needed for effective cancer treatment, while also reducing severe side effects. Affimed aims to address these challenges by redirecting immune cells with multi-specific antibodies to achieve optimized killing of malignant cells.

Leveraging our modular and versatile ROCK® (Redirected Optimized Cell Killing) platform, we generate proprietary, next-generation bispecific antibodies. Our tetravalent (four binding sites) bispecific (two targets) immune cell engagers have the ability to bring NK cells or T cells into proximity to cancer cells and trigger a signal cascade that leads to the destruction these cancer cells.

A number of clinical and preclinical programs are in development based on the ROCK® platform and our tetravalent bispecific immune cell engagers have already shown a favorable safety profile and promising signs of therapeutic efficacy.

We believe that our product candidates, alone or in combination with other agents (e.g. checkpoint modulators, adoptive NK cells or cytokines), may ultimately improve clinical outcomes in cancer patients and could eventually become a key element of modern targeted oncology care.

Affimed was founded in 2000 based on technology developed by the group led by Professor Melvyn Little at Deutsches Krebsforschungszentrum, the German Cancer Research Center, or DKFZ, in Heidelberg. In 2009, Affimed set up its wholly owned unit AbCheck in Pilsen, Czech Republic, which focuses on fully human antibody screening and optimization.